SML0074
醋硝香豆素
≥98% (HPLC)
别名:
(±)-Acenocoumarin, 3-(α-Acetonyl-p-nitrobenzyl)-4-hydroxy-coumarin
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C19H15NO6
化学文摘社编号:
分子量:
353.33
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
205-807-3
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to tan
solubility
DMSO, heptane and xylene: ≥17 mg/mL
originator
Novartis
storage temp.
−20°C
SMILES string
CC(=O)CC(c1ccc(cc1)[N+]([O-])=O)C2=C(O)c3ccccc3OC2=O
InChI
1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3
InChI key
VABCILAOYCMVPS-UHFFFAOYSA-N
Gene Information
human ... VKORC1(79001)
Application
Acenocoumarol was used to study the role of P-glycoprotein in transport of oral vitamin K in Caco-2 cells and as an LC/MS standard.
Acenocoumarol has been used as a standard for the determination of coumarins in cosmetics.
Biochem/physiol Actions
Acenocoumarol is a warfarin analog, an anticoagulant that inhibits Vitamin K epoxide reductase. This results in depletion of the reduced form of vitamin K (vitamin KH2), limiting the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S, resulting in decreased prothrombin levels and the amount of thrombin generated.
Warfarin analog; anticoagulant; inhibitor of Vit K epoxide reductase
Acenocoumarol is effective against thromboembolic disorders.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
Antonio J Carcas et al.
Trials, 13, 239-239 (2012-12-15)
Hemorrhagic events are frequent in patients on treatment with antivitamin-K oral anticoagulants due to their narrow therapeutic margin. Studies performed with acenocoumarol have shown the relationship between demographic, clinical and genotypic variants and the response to these drugs. Once the
Liliane Gschwind et al.
Basic & clinical pharmacology & toxicology, 113(4), 259-265 (2013-05-15)
Vitamin K antagonists (VKAs) are prescribed worldwide and remain the oral anticoagulant of choice. These drugs are characterized by a narrow therapeutic index and a large inter- and intra-individual variability. P-glycoprotein could contribute to this variability. The aim of this
Determination of Coumarins in Cosmetics
Application Note, 1128 (2016)